Women & HIV Back grey_arrow_rt.gif
 
AIDS is the leading cause of death among African American and Hispanic women ages 25-44 in the US. African American and Hispanic women accounted for 76% of new AIDS cases among women reported in 1996 in the US. Women are one of the fastest growing groups of new AIDS cases, accounting for 20% of newly reported cases in the US and 42% of new cases worldwide. In clinical research on potential treatments, only 12% of research participants are female. Women are 33% more likely to die than men because treatment begins so much later, if at all.
 
null.gif
 
 
  1. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)
     
  2. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  3. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  4. CROI: Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)
     
  5. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  6. CROI: PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)
     
  7. Undertreated midlife symptoms for women living with HIV linked to lack of menopause discussions with providers - menopausal hormone therapy under-utilized - (02/07/22)
     
  8. Menopause Is Associated With Immune Activation in Women With HIV - (01/19/22)
     
  9. Women with HIV Have More Comorbidities, Worse Physical Function, & Inflammation - (01/07/22)
     
  10. Faces of Frailty [women] in Aging with HIV Infection - (01/07/22)
     
  11. Focus Groups - 2015 - WIHS-Wash DC - Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts - (10/17/21)
     
  12. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (10/17/21)
     
  13. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women - (10/17/21)
     
  14. Co-located HIV Services Can Help Women Who Inject Drugs Access PrEP, Study Shows - (10/17/21)
     
  15. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States - (10/17/21)
     
  16. ART & Cervical Cancer Women with HIV Risk - (07/14/21)
     
  17. 2 New studies: Diabetes-Depression-Women & High Suicide Rates PLWH - (07/09/21)
     
  18. CROI: Women & HIV at CROI - (03/28/21)
     
  19. CROI: SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)
     
  20. HIV+ Women Have Higher Burden of Comorbidities vs HIV- Women / Accelerated-Earlier by 10 Years - (03/02/21)
     
  21. HIV+ Women & MSM: aging & other issues - (02/22/21)
     
  22. Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy - (12/15/20)
     
  23. Disparate Impact of HIV/Aging on women - (06/30/20)
     
  24. HIV Neuropathy: Women & Men/Prevalence-Risk Factors - (06/30/20)
     
  25. HCV & Women - several key reports - (03/10/15)
     
  26. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14)
     
  27. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study - (03/15/13)
     
  28. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13)
     
  29. The Association of Race, Sociodemographic, and Behavioral Characteristics With Response to Highly Active Antiretroviral Therapy in Women: 'depression, black/latino women, HAART discontinuation, higher death rates, drug use all related' - (04/03/12)
     
  30. Women & HIV: Medical Care for Menopausal and Older Women With HIV Infection - (03/29/12)
     
  31. Women & HIV: Testosterone & HIV+ Women - adverse events - (03/29/12)
     
  32. Women & HIV: Gender Gap in CVD: The Epidemiology of Cardiovascular Disease in Postmenopausal Women-see article below - (03/29/12)
     
  33. Women & HIV: Sex Differences in the Pharmacologic Effects of Antiretroviral Drugs: Potential Roles of Drug Transporters and Phase 1 and 2 Metabolizing Enzymes - (03/29/12)
     
  34. Women & HIV: Women & HIV: Black Women in USA; trauma; childhood sex abuse; heart disease in HIV+ women - (03/29/12)
     
  35. Women & HIV: Heart Disease & Women HIV+, inflammation: Obesity and Dyslipidemia in Behaviorally HIV-Infected Young Women: Adolescent Trials Network Study 021 - (03/29/12)
     
  36. Women & HIV: Gender differences in the treatment of HIV infection - review - (03/29/12)
     
  37. 2nd Intrntnl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/11/12)
     
  38. 2nd Intrntnl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
     
  39. 2nd Intrntnl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
     
  40. 2nd Intrntnl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
     
  41. 2nd Intrntnl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
     
  42. 2nd Intrntnl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
     
  43. 2nd Intrntnl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
     
  44. 2nd Intrntnl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
     
  45. 2nd Intrntnl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
     
  46. 2nd Intrntnl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
     
  47. 2nd Intrntnl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
     
  48. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
     
  49. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
     
  50. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
     
  51. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
     
  52. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
     
  53. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
     
  54. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
     
  55. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
     
  56. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
     
  57. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
     
  58. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
     
  59. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
     
  60. 1st Intrnl Wrkshp HIV & Women: Microbicide Disclosure to Partners Did & Results of CAPRISA 004 - written by Mark Mascolini - (01/11/11)
     
  61. 1st Intrnl Wrkshp HIV & Women: Striking Regional Antiretroviral Response Differences Found in Canadian Women - written by Mark Mascolini - (01/11/11)
     
  62. 1st Intrnl Wrkshp HIV & Women: Violence Linked to Substance Use and Mental Health in BC Women With HIV - written by Mark Mascolini - (01/11/11)
     
  63. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - written by Mark Mascolini - (01/11/11)
     
  64. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - written by Mark Mascolini - (01/11/11)
     
  65. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - written by Mark Mascolini - (01/11/11)
     
  66. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
     
  67. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  68. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
     
  69. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  70. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
     
  71. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
     
  72. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  73. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  74. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  75. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  76. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  77. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/09)
     
  78. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  79. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  80. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  81. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  82. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (08/03/09)
     
  83. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  84. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  85. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  86. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  87. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  88. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  89. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  90. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  91. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  92. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  93. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  94. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  95. Routine HIV testing recommended for women - (04/08/09)
     
  96. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  97. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  98. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  99. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
     
  100. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
     
  101. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
     
  102. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
     
  103. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women: "Our findings show that the prevalence of AIN among HIV-infected women is high and significantly increased above a comparison group of HIV-uninfected women." - (12/15/08)
     
  104. HIV CRISIS: AIDS is the leading cause of death for African-American women ages 25-34 today - (10/31/08)
     
  105. HIV Doctors May Treat All Infected, Adding Thousands: When To Start HAART Debate - (10/31/08)
     
  106. ICAAC: Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08)
     
  107. ICAAC: Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08)
     
  108. ICAAC: Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)
     
  109. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women - (10/08/08)
     
  110. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  111. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors - (10/08/08)
     
  112. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  113. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle - (09/23/08)
     
  114. Breast milk purged of HIV virus by Nipple Shield+Chemical - (09/22/08)
     
  115. HAART, Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire - (09/18/08)
     
  116. Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission - (09/8/08)
     
  117. IAS: Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) -
     
  118. IAS: Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) -
     
  119. IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) -
     
  120. IAS: HIV Crosses the Gender Divide - (08/19/08) -
     
  121. Enhancement of HIV Infection by Cellulose Sulfate - (07/31/08)
     
  122. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (07/31/08)
     
  123. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort - (07/29/08)
     
  124. Extended nevirapine prophylaxis to prevent HIV transmission - (07/29/08)
     
  125. Viagra for Women with Antidepressant-Associated Sex Dysfunction - (07/25/08)
     
  126. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
     
  127. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
     
  128. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  129. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  130. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
     
  131. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
     
  132. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN - (12/28/07)
     
  133. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
     
  134. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine (09/26/07)
     
  135. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  136. Diaphragm and lubricant gel + Condom for prevention of HIV acquisition in southern African women: a randomised controlled trial - (07/19/07)
     
  137. U.S. NIH Funded Trial of VivaGel in Sexually Active Young Women Commences - (07/17/07)
     
  138. "He Won't Use Condoms": HIV-Infected Women's Struggles in Primary Relationships With Serodiscordant Partners - (07/02/07)
     
  139. Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV-Infected Women - (06/20/07)
     
  140. Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens in WIHS (Women) - (05/22/07)
     
  141. Hysterectomy Among Women With HIV: Indications and Incidence - (05/22/07)
     
  142. Resistance to Antiretroviral Drugs: A Threat to the Prevention and Treatment of Pediatric HIV Infection EDITORIAL COMMENTARY - (05/03/07)
     
  143. Early Archiving and Predominance of NNRTI-Resistant HIV-1 among Recently Infected Infants Born in the United States - (05/03/07)
     
  144. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children - (04/29/07)
     
  145. Assessment of Birth Defects According to Maternal Therapy Among Infants in the Women and Infants Transmission Study (WITS) - (04/03/07)
     
  146. Use of ART in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis - (04/03/07)
     
  147. Dose-Ranging Phase 1 Study of TMC120, a Promising Vaginal Microbicide, in HIV-Negative and HIV-Positive Female Volunteers - (02/23/07)
     
  148. Safety of nevirapine in pregnancy - (01/19/07)
     
  149. Extra-Hepatic HCV in HIV+ Women: Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Antibody HCV-Positive/HIV-Infected Women - (01/03/07)
     
  150. Cervical Shedding of HIV-1 RNA Among Women With Low Levels of Viremia While Receiving HAART - (01/04/07)
     
  151. Discontinuation of ART Postpartum: No Evidence for Altered Viral Set Point [Letters to the Editor] - (01/04/07)
     
  152. Human Papilloma Virus (HPV) Infection of the Anus Is More Prevalent and Diverse than Cervical HPV Infection among HIV-Infected Women in the SUN Study - (12/08/06)
     
  153. Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy - (12/08/06)
     
  154. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States / Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy - (10/20/06)
     
  155. ICAAC: Tenofovir and Lopinavir Levels in Pregnant Women and Infants - Written for NATAP by Mark Mascolini - (10/16/06)
     
  156. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities - (09/12/06)
     
  157. Longitudinal Analysis of Bone Density in HIV-Infected Women - (09/06/06)
     
  158. The mother-to-child HIV transmission epidemic in Europe (Ukraine & Eastern Europe): evolving in the East and established in the West - (07/17/06)
     
  159. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women - (05/17/06)
     
  160. HAART & Fetal death/Pre-eclampsia - (04/24/06)
     
  161. Antioxidant supplementation in pre-eclampsia: Commentary - (04/24/06)
     
  162. Heart Disease Prevention in Women (men too) - (04/24/06)
     
  163. Errors in Celia Farber's March 2006 article in Harper's Magazine - (03/15/06)
     
  164. HCV Mother-to-child transmission: HAART May Reduce HCV MTC; C-Section Did Not Reduce MTC - (03/15/06)
     
  165. HIV-Positive Latina Immigrants in California - (02/28/06)
     
  166. CROI: Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV (02/27/06)
     
  167. Tenofovir may be safe as vaginal HIV microbicide - (02/24/06)
     
  168. CROI: Tenofovir Achieves High Levels in the Genital tract of Men & Women and Reduces HIV RNA in Genital Tract of Men & Women (02/13/06)
     
  169. WISE Study of Women and Heart Disease Yields Important Findings on Frequently Undiagnosed Coronary Syndrome - (01/31/06)
     
  170. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
     
  171. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
     
  172. Experimental vaginal gel inhibits HIV and HSV - (01/25/06)
     
  173. PRO 2000 Gel Inhibits HIV and Herpes Simplex Virus Infection Following Vaginal Application: A Double-Blind Placebo-Controlled Trial - (01/05/06)
     
  174. Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier Protection - (01/05/06)
     
  175. HCV Transmission Risks from Mother-To-Child up to 6.2% - (11/09/05)
     
  176. Vaginal Microbicide Gel Phase III Study Enrolled - (10/28/05)
     
  177. Vaginal Gel Trials Start in South Africa - (10/28/05)
     
  178. Microbicide Study in Women Begins - (10/25/05)
     
  179. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women - (10/05/05)
     
  180. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  181. Protease Inhibitor Use in 233 Pregnancies - (09/14/05)
     
  182. Therapy-associated severe hyperlactatemia rare in HIV patients - (09/02/05)
     
  183. 2 Articles on Pregnancy in HIV: HAART & Congential Abnormalities; Mitochondrial Toxicity in Uninfected Newborns - (09/02/05)
     
  184. IAS: Atazanavir Use in Pregnancy (08/05/05)
     
  185. Low-dose oral contraceptives increase cardiovascular disease risk - (07/13/05)
     
  186. High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women - (07/20/05)
     
  187. Safety, Acceptability, and Potential Efficacy of a Topical Penile Microbicide Wipe - (07/08/05)
     
  188. HIV-Positive U.S. Women More Concentrated in South, Among Minorities, CDC Says at HIV Prevention Conference in Atlanta - (06/16/05)
     
  189. Early antiretroviral therapy decreases progression of perinatal HIV - (05/13/05)
     
  190. EASL: HIV & High HCV Viral load Increased HCV Perinatal Transmission (05/05/05)
     
  191. Body Changes in Women Associated with Heart Disease Risk: "Increased Cardiovascular Disease Risk Indices in HIV-Infected Women" - (05/04/05)
     
  192. HIV load and CD4+ cell count affect HPV detection in HIV-infected women - (04/22/05)
     
  193. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy - (04/12/05)
     
  194. 25% of Women in WIHS Stop HAART for at least 6 Months - (04/01/05)
     
  195. Gender Affect in HIV & HAART - (04/01/05)
     
  196. "Women At Risk: The Health of Women in New York City" Report Released - (04/01/05)
     
  197. CROI: Prevention of mother-to-child transmission and nevirapine resistance - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  198. Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (02/07/05)
     
  199. Fat Distribution in HIV-Infected Women in the United States: DEXA Substudy in the Women's Interagency HIV Study - (12/21/04)
     
  200. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with HAART in Europe - (12/15/04)
     
  201. Protease Inhibitor and NNRTI Concentrations in the Genital Tract of HIV+ Women - (12/06/04)
     
  202. HIV-Associated Anal Cancer: Has Highly Active Antiretroviral Therapy Reduced the Incidence or Improved the Outcome? - (12/06/04)
     
  203. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/04)
     
  204. HAART Resolves Life-Threatening Anemia in Women - (10/05/04)
     
  205. Women & HIV-CDC Updates HIV/AIDS Surveillance Among Women in US - (09/27/04)
     
  206. Glaxo AIDS Drugs to Be Tested In Topical Form, as Microbicide - (09/24/04)
     
  207. Depression & No HAART Increases Risk for AIDS-Death Among HIV+ Women in WIHS - (09/21/04)
     
  208. Nelfinavir Plasma Concentrations Are Low during Pregnancy - (09/07/04)
     
  209. Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (08/30/04)
     
  210. Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, avascular necrosis, mitochondrial toxicity - (08/20/04)
     
  211. XV International AIDS Conference in Bangkok: IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)
     
  212. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe - (07/01/04)
     
  213. Cancer Risk Among Participants in the Women's Interagency HIV Study - (06/30/04)
     
  214. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery - (06/28/04)
     
  215. Persistance of HPV in HIV+ Adolescent Girls - (06/28/04)
     
  216. Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 - (06/22/04)
     
  217. Contraceptive Use in HIV-Positive Women - (06/07/04)
     
  218. NRTIs and Intracellular Activity and Toxicities for Women, Advanced HIV & Hepatitis - (05/17/04)
     
  219. Smoking Increases Risk for Cervical Cancer in HIV+ - (05/10/04)
     
  220. Famcyclovir for Herpes Simplex Virus Shedding in Women - (05/10/04)
     
  221. Gender, Pregnancy, and PKs - (05/10/04)
     
  222. Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update - (05/04/04)
     
  223. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir - (05/03/04)
     
  224. Women with HIV can benefit from testosterone treatment - (04/27/04)
     
  225. Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus Associated Genital Lesions in HIV-Positive Women - (04/05/04)
     
  226. HIV in Semen, Effect of HAART, Sexual Transmission of HIV, & Relevance in Getting Pregnant - (03/31/04)
     
  227. Reduced bone density in HIV-infected women - (03/10/04)
     
  228. Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (02/23/04)
     
  229. CROI: HIV Microbocides at the 11th Retrovirus Conference - (02/23/04)
     
  230. The effect of hormonal contraception on genital tract shedding of HIV-1 - (02/06/04)
     
  231. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program in WIHS Study - (01/26/04)
     
  232. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes - (01/05/04)
     
  233. AZT Monotherapy To Prevent Perinatal Transmission - (01/05/04)
     
  234. Increased Risk for Fat Loss in HIV+ Women Observed in WIHS Study - (12/08/03)
     
  235. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
     
  236. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
     
  237. EACS - HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
     
  238. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals - (10/8/03)
     
  239. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women - (9/30/03)
     
  240. Microbicides: STD Protection With or Without Contraception - (8/18/03)
     
  241. Background Information Microbicide Drug Candidates Including Cyanovirin-N To Prevent Anal & Vaginal HIV Transmission - (8/18/03)
     
  242. FDA Hearing on Microbicides to Prevent HIV Transmission to Women: trial considerations - (8/18/03)
     
  243. Sperm washing in the UK: evidence of safety and efficacy - (4/30/03)
     
  244. High Rates of Viral Infections & HCV and For Risk Factors Among HIV-Infected and High-Risk HIV-Uninfected Women - (4/21/03)
     
  245. Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV-Infected Women - (4/2/03)
     
  246. Prevalence of Genotypic Drug Resistance Among a Cohort of HIV-Infected Newborns: suggesting resistance testing in newborns - (4/2/03)
     
  247. HCV in Semen - (3/26/03)
     
  248. Night Before or After Pill To Prevent HIV Transmission - (3/17/03)
     
  249. Retro - Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (3/10/03)
     
  250. Resistance Testing Recommended For Pregnant Women: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Observed Among Antiretroviral-Naive HIV-Positive Pregnant Women - (3/6/03)
     
  251. Perinatal Hepatitis C Virus Transmission: Role of Human Immunodeficiency Virus Infection and Injection Drug Use - Gregory L. Armstrong, Joseph F. Perz, and Miriam J. Alter Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia - (2/28/03)
     
  252. Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)Specific T Cell Responses in Primary HIV Infection - (2/26/03)
     
  253. Tale of Two Epidemics: The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus - (2/26/03)
     
  254. Retroconference Update: HIV and Women Written for NATAP by Judith Aberg, MD, Washington University, St Louis, MO, ACTG - (2/24/03)
     
  255. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women - (12/02/02)
     
  256. Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)
     
  257. Viral load in HCV RNA-positive pregnant women - (9/18/02)
     
  258. Hep C & Pregnancy: risks for transmission - (9/18/02)
     
  259. Does Patient Gender Affect Human Immunodeficiency Virus Levels? - (9/13/02)
     
  260. Women With Impaired Glucose Tolerance During Pregnancy Have Significantly Poor Pregnancy Outcomes - (8/27/02)
     
  261. Depression & Anxiety Can Occur in Diabetics and Their Partners, Particularly Women - (8/27/02)
     
  262. Sperm Washing for Pregnancy in HIV - (8/27/02)
     
  263. Barcelona - Anal Sex Increases Risk For Heterosexual HIV Transmission - (7/17/02)
     
  264. Kaletra in Women - (7/12/02)
     
  265. Recurrence rate of cervical dysplasia high in HIV-positive women - 06/12/02
     
  266. Women and HCV - (06/03/02)
     
  267. GILEAD ANNOUNCES INITIATION OF NIH-SPONSORED PHASE I TRIAL TO EVALUATE TENOFOVIR TOPICAL GEL AS PREVENTIVE FOR VAGINAL TRANSMISSION OF HIV - (05/22/02)
     
  268. Women with HIV: More conference time Written for NATAP by Judith Aberg, MD, Washington University, Director of HIV Clinic, St Louis - (03/19/02)
     
  269. Maternal - Fetal Transmission at Retrovirus Written by Danielle Milano, MD, Boriken Family Health Services, New York - (03/18/02)
     
  270. HIV and Women at Retrovirus Written for NATAP by Danielle Milano, MD, Boriken Family Health Services, NYC - (03/18/02)
     
  271. Kidney failure in Women with HIV - (02/21/02)
     
  272. HIV Therapy for Pregnant Women - (02/20/02)
     
  273. AIDS Experts Cite New Opportunities: women/minorities/pregnancy by Vanessa Palo- The Associated Press - (02/11/02)
     
  274. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women - (12/27/01)
     
  275. IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C - (12/03/01)
     
  276. Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy - (11/01/01)
     
  277. Screening for Anal and Cervical Dysplasia in HIV-Infected Patients PDF - (10/11/2001)
     
  278. Discontinuation of primary Pneumocystis carinii prophylaxis after reconstitution of CD4 cell counts in HIV-infected children - (9/14/01)
     
  279. Preventing disease by protecting the cervix: the unexplored promise of
    internal vaginal barrier devices
     (with PDF attached) - (9/20/01)
     
  280. Mother-to-Infant Transmission of Hepatitis C Virus - with full version in PDF format - (9/14/01)
     
  281. Gynecologic Problems for Women with HIV - in PDF format only from A Guide to the Clinical Care of Women with HIV - (9/10/01)
     
  282. Italian Study Finds HIV Delays Sexual Maturation in Boys & Girls Infected by their Mothers - (8/27/01)
     
  283. Gender Differences in Morphologic Alterations (Body Changes or Lipodystrophy) - (8/27/01)
     
  284. Mother-to-Child Transmission - (8/27/01)
     
  285. Role of HAART in Development of Hypertension Among HIV-Infected Women - (8/27/01)
     
  286. Access to Care for Women - (8/27/01)
     
  287. HPV Infection in Women and Men - Written for NATAP by Danielle Milano, MD - (8/2/01)
     
  288. HCV & Pregnancy, risk factors for transmission: breastfeeding, c-section, use of forceps in delivery - (8/1/01)
     
  289. Prevalence and Risk Factors for Anal Squamous Intraepithelial Lesions in Women - (6/15/2001)
     
  290. Immune Suppression and the Risk for Cervical Dysplasia - (5/15/2001)
     
  291. Women in HIV: - Highlights from the 8th Annual Retrovirus Conference (in simpler easier-to-read version)
    Written for NATAP by Kathleen Squires, MD, edited by Jules Levin, NATAP (3/07/2001)
     
  292. HIV Infection in Women - Reported for NATAP by Kathleen Squires, MD - (3/5/2001)
     
  293. Selected Highlights on HIV Transmission, Women & Children: HAART reduces perinatal transmission - (2/19/2001)
     
  294. Transmission From Mother to Newborn is Preventable if Viral Load is <1000 copies/ml at Delivery (1%) - (2/19/2001)
     
  295. HAART has a beneficial effect for women with HIV with Cervical Intraepithelial Neoplasia (CIN) - (2/19/2001)
     
  296. Women and Children Get HIV Also! - by Judith A. Aberg, M.D
     
  297. Women and Clinical Trials
     
  298. The HIV-Positive Woman: Are You Getting Good Medical Care? - by Debra Johnson, NP, PA-C and Kathleen E. Squires, MD - (2/16/2001)